MyHep All is a breakthrough, all-oral antiviral medication used to treat all genotypes of chronic Hepatitis C infection. It contains Sofosbuvir (400 mg) and Velpatasvir (100 mg), offering a complete, once-daily treatment solution with a high cure rate and minimal side effects.
MyHep All is a powerful fixed-dose combination medication manufactured by Mylan Pharmaceuticals for the treatment of chronic Hepatitis C in adults. It contains Sofosbuvir 400 mg, a nucleotide polymerase inhibitor, and Velpatasvir 100 mg, an NS5A inhibitor. Together, these direct-acting antivirals (DAAs) stop the virus from multiplying and eliminate it from the body.
Approved for treatment across all six major genotypes (genotype 1-6) of HCV, MyHep All simplifies therapy by offering a pangenotypic, once-daily oral tablet—no need for interferon or ribavirin in most cases. The standard treatment duration is 12 weeks, often resulting in a sustained virologic response (SVR), which is considered a cure.
Key Features:
Pangenotypic – treats all genotypes of Hepatitis C
High cure rate (SVR) after a 12-week course
Once-daily oral tablet for ease of use
Minimal side effects in most patients
Manufactured by the trusted brand Mylan
Usage & Dosage:
Dosage: One tablet daily, with or without food
Treatment duration: Typically 12 weeks
Always take the medication exactly as prescribed. Continue to use for the full prescribed length of time, even if symptoms improve earlier.
Precautions:
Not recommended for use in patients with severe kidney disease without physician approval
Not for use during pregnancy or breastfeeding unless advised by a healthcare provider
Inform your doctor about all current medications to avoid drug interactions
Regular liver function and viral load tests are needed during treatment
Storage Instructions:
Store at room temperature (15°C to 30°C)
Keep away from moisture and direct sunlight
Keep out of reach of children
